As genotyping costs fall, clinically validated variants, particularly those in NOS3, MMPs, and CYP4A11, may contribute to personalized hypertension management, guiding early screening and pharmacogenetic interventions. The gene discussed is CYP4A11; the disease is hypertensive disorder.